{"hq_id":"hq-c-org-000215","name":"Flunitrazepam (Rohypnol)","context":"human_adult","timestamp":"2026-10-27T20:20:36.980Z","derived_by":{"label":"ALETHEIA-derived","engine":{"commit":"a1c6e861599cc34c5db0318ea1a7ac13a327e074","commit_source":"vercel_env","tree_clean":null},"params":{"sha256":"88ae43137e58ed0cd65588409efefee0d90253da01ef4459bf9ee25f888ec9a0","files":["axes.json","context-specificity.json","regulatory-mappings.json","synthesis-params.json","thresholds.json"]},"clock":{"year":2026},"inputs":[{"id":"hq-c-org-000215","sha256":"71ad4b985a201dc710e6ab0f54852cf06a824aca2a67d6925356700642d39b18"}]},"risk_level":"high","risk_profile":{"magnitude":{"mean":0.625,"weightedMean":0.625,"std_dev":0,"confidence_interval_95":[0.625,0.625],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.625,"weight":0.35}]},"confidence":{"mean":0.5,"weightedMean":0.5,"std_dev":0,"confidence_interval_95":[0.5,0.5],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.5,"weight":0.35}]},"recency":{"mean":1,"weightedMean":1,"std_dev":0,"confidence_interval_95":[1,1],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":1,"weight":0.35}]},"methodology":{"mean":0.7,"weightedMean":0.7,"std_dev":0,"confidence_interval_95":[0.7,0.7],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.7,"weight":0.35}]},"specificity":{"mean":0.92,"weightedMean":0.92,"std_dev":0,"confidence_interval_95":[0.92,0.92],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.92,"weight":0.35}]},"consensus":{"exists":false,"strength":0,"disagreement_magnitude":0,"warning":"single_source_warning"}},"interpretation":{"summary":"Single source (HQ_DIRECT, 2026) indicates high risk.","confidence_note":"Evidence quality varies; interpretation requires caution.","context_note":null,"warning":"single_source_warning"},"sources":[{"id":"dea_flunitrazepam_scheduling","type":"regulatory","title":"US DEA: Flunitrazepam (Rohypnol) — Schedule IV Classification, Drug-Facilitated Sexual Assault Profile, Blue Dye Reformulation (1990s), Detection Window and GC-MS Testing Requirements, and US Import Prohibition (2022)","year":2022},{"id":"samhsa_dfsa_report","type":"regulatory","title":"SAMHSA: Drug-Facilitated Sexual Assault — Flunitrazepam, GHB, and Other Substances; Victim Presentation, Forensic Evidence Collection, Urine/Blood Testing Protocols, Adolescent Victim Demographics, and Clinical Recognition Guidelines (2019)","year":2019},{"id":"r60-2026-10-01-dd54-ecfr-21cfr-part-1308","type":"regulatory","title":"21 CFR part 1308 (eCFR versioner full XML, up to date as of 2026-09-25)","url":"https://www.ecfr.gov/api/versioner/v1/full/2026-09-25/title-21.xml?part=1308"},{"id":"r60-2026-09-30-d918-oehha-prop65-list-csv-own-url","type":"regulatory","title":"OEHHA Proposition 65 List of Carcinogens or Reproductive Toxicants (CSV, list date 31-Jul-26)","url":"https://oehha.ca.gov/sites/default/files/media/2025-01/p65chemicalslist.csv"},{"id":"r60-2026-10-02-d-955-s9-d955-s9-osha-table-z-1","type":"regulatory","title":"Permissible Exposure Limits – OSHA Annotated Table Z-1","url":"https://www.osha.gov/annotated-pels/table-z-1"},{"id":"ctx_pred_dtxsid7023065","type":"reference","title":"EPA CompTox CTX API: predicted properties for DTXSID7023065 (Flunitrazepam (Rohypnol))","url":"https://comptox.epa.gov/ctx-api/chemical/property/predicted/search/by-dtxsid/DTXSID7023065"}],"sources_scope":"context","derived_markers":[],"warnings":["unmapped_classification:DEA:schedule iv","single_source_warning"],"meta":{"synthesis_version":"1.1.0","config_version":"1.1.0","n_sources":1,"db_version":42,"warnings":["unmapped_classification:DEA:schedule iv"]},"schema":"synthesis","_notice":"ALETHEIA output is reference data, not professional advice. Not a substitute for primary agency sources or qualified professionals. See https://aletheia.holisticquality.io/disclaimer.","_disclaimer_url":"https://aletheia.holisticquality.io/disclaimer","available_contexts":["human_adult","human_child","dog","human_teen","human_elderly","human_infant","human_pregnant"]}